Monoclonal antibody

Alchemab raises £60M ($82M) in Series A financing to advance novel platform for identifying disease-modifying antibody therapeutics

Thursday, April 15, 2021 - 9:00am

The company was created by SV Health Investors who led the Seed round in 2019.\nThe proceeds will be used to advance Alchemab\xe2\x80\x99s unique target-agnostic drug discovery platform.

Key Points: 
  • The company was created by SV Health Investors who led the Seed round in 2019.\nThe proceeds will be used to advance Alchemab\xe2\x80\x99s unique target-agnostic drug discovery platform.
  • The approach interrogates the entire antibody repertoires of individuals from well-defined groups who show unexpected resistance to disease despite genetic disposition or other risk factors predicative of a poor prognosis.
  • Using insights gained, Alchemab can identify naturally protective antibodies with therapeutic potential.
  • The Series A financing offers a great opportunity to accelerate our efforts to positively impact the lives of patients.\nDr Houman Ashrafian, Managing Partner at SV Health Investors, commented: \xe2\x80\x9cAlchemab is a brilliant company driven by science.

Gemini Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Tuesday, April 13, 2021 - 1:00pm

b'Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degeneration (AMD), today announced the grant of an inducement award to Brian Piekos, Gemini\xe2\x80\x99s Chief Financial Officer and the grant of an inducement award to Dr. Sam Barone, Gemini\xe2\x80\x99s Chief Medical Officer.

Key Points: 
  • b'Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degeneration (AMD), today announced the grant of an inducement award to Brian Piekos, Gemini\xe2\x80\x99s Chief Financial Officer and the grant of an inducement award to Dr. Sam Barone, Gemini\xe2\x80\x99s Chief Medical Officer.
  • Gemini\xe2\x80\x99s lead candidate, GEM103, is a recombinant form of human complement factor H protein (CFH) and is designed to address both complement hyperactivity and restore retinal health in patients with AMD.
  • GEM103 is currently in a Phase 2a trial in dry AMD patients with a CFH risk variant and a Phase 1/2a study in patients with neovascular age-related macular degeneration with or at risk for macular atrophy.
  • The company has generated a rich pipeline including recombinant proteins, gene therapies, and monoclonal antibodies and is advancing a potentiating antibody for CFH, GEM307, into clinical development for treatment of systemic diseases.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210413005475/en/\n'

Waters and Genovis Collaborate to Develop Efficient Workflows for Biopharmaceutical Characterization

Tuesday, April 13, 2021 - 1:00pm

b'Waters Corporation (NYSE:WAT) and Genovis AB (Nasdaq First North Growth Market) are formally collaborating to develop and market complete routine biopharmaceutical characterization workflows based on the Waters\xe2\x84\xa2 BioAccord\xe2\x84\xa2 LC-MS System , Andrew+ pipetting robot and Genovis SmartEnzymes\xe2\x84\xa2 .

Key Points: 
  • b'Waters Corporation (NYSE:WAT) and Genovis AB (Nasdaq First North Growth Market) are formally collaborating to develop and market complete routine biopharmaceutical characterization workflows based on the Waters\xe2\x84\xa2 BioAccord\xe2\x84\xa2 LC-MS System , Andrew+ pipetting robot and Genovis SmartEnzymes\xe2\x84\xa2 .
  • The goal of the collaboration is to develop automated workflows for the rapid and consistent characterization of critical quality attributes (CQAs) of monoclonal antibodies (mAbs) and other protein-based drugs in bioprocess development, formulation, stability testing and quality control (QC).\nThis press release features multimedia.
  • View the full release here: https://www.businesswire.com/news/home/20210413005369/en/\n\xe2\x80\x9cBiologics analysis is an area that is ripe for improvement.
  • What takes analytical scientists several days to do, should take hours or minutes instead,\xe2\x80\x9d said Jeff Mazzeo, Vice President, Global Marketing and Scientific Operations, Waters Corporation.

PureTech Presents Promising Preclinical Data from LYT-210 Immuno-Oncology Program at American Association for Cancer Research (AACR) Annual Meeting

Monday, April 12, 2021 - 12:00pm

View the full release here: https://www.businesswire.com/news/home/20210412005194/en/\nPureTech announced the presentation of a scientific poster detailing additional promising preclinical results for its LYT-210 antibody at the 2021 AACR Annual Virtual Meeting.

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20210412005194/en/\nPureTech announced the presentation of a scientific poster detailing additional promising preclinical results for its LYT-210 antibody at the 2021 AACR Annual Virtual Meeting.
  • (Photo: Business Wire)\nLYT-210 is a novel, fully human monoclonal antibody (mAb) directed against T cells bearing \xce\xb3\xce\xb41 receptors, which are known to suppress the anti-tumor immune response.
  • The research was conducted in vitro using both patient blood and cancer tissue.
  • \xe2\x80\x9cWe are excited by these new data demonstrating that our LYT-210 therapeutic candidate can precisely target and swiftly deplete pathogenic \xce\xb3\xce\xb41 T cells.

Worldwide Industry for Research Antibodies to 2025 - by Product, Clonality, Major Reactivities, Application, Host Species, End-user and Region

Wednesday, April 14, 2021 - 11:30pm

Research and market trends are also extrapolated by analyzing the funding, patent publications and sales trends of major players in the field.\nIn this report, the market for research antibodies is segmented based on product type, major reactivities, applications, and geography.

Key Points: 
  • Research and market trends are also extrapolated by analyzing the funding, patent publications and sales trends of major players in the field.\nIn this report, the market for research antibodies is segmented based on product type, major reactivities, applications, and geography.
  • Moreover, the advancement of biological discoveries will result inthe need for more molecular targets to be detected by their antibodies.
  • For example, even for the same protein molecule, antibodies for each of its many forms of post-translational modifications are needed.
  • This is likely to propel the growth of the research antibodies market during the forecast period.\nPrimary antibodies are used alone or in combination with a secondary antibody.

Bio-Techne Announces Licensing of Proprietary Antibody to Xencor for Therapeutic Development

Wednesday, April 14, 2021 - 12:00pm

This is Bio-Techne\'s third licensing agreement with Xencor, a leader in protein engineering in the immuno-oncology field.

Key Points: 
  • This is Bio-Techne\'s third licensing agreement with Xencor, a leader in protein engineering in the immuno-oncology field.
  • Under the terms of this agreement, Bio-Techne grants Xencor access to a proprietary Bio-Techne antibody for use with their proprietary XmAb protein engineering technology, which is revolutionizing the development of new cancer therapeutics such as bispecific antibodies and engineered cytokines.\n"We are extremely excited about this agreement with Xencor.
  • Our goal for antibody development is to create highly specific antibodies against important therapeutic targets.
  • "We are proud of our long history of being the partner of choice for therapeutic antibody discovery and our innovative antibody discovery platform that is harnessed by our pharma customers to fast-track their therapeutic programs.

Harbour BioMed Presents Novel Antibody for Cancer Immunotherapy at 2021 American Association for Cancer Research Annual Meeting

Tuesday, April 13, 2021 - 7:55am

b'CAMBRIDGE, Mass., SUZHOU, China andROTTERDAM, Netherlands, April 13, 2021 /PRNewswire/ -- Harbour BioMed ("HBM"; HKEX: 02142.HK), a global clinical-stage biopharmaceutical company,presents its newly discovered fully human anti-B7H7 monoclonal antibody at the American Association for Cancer Research Annual Meeting.

Key Points: 
  • b'CAMBRIDGE, Mass., SUZHOU, China andROTTERDAM, Netherlands, April 13, 2021 /PRNewswire/ -- Harbour BioMed ("HBM"; HKEX: 02142.HK), a global clinical-stage biopharmaceutical company,presents its newly discovered fully human anti-B7H7 monoclonal antibody at the American Association for Cancer Research Annual Meeting.
  • This meeting is being held virtually from April 10-15, 2021.
  • The anti-B7H7 antibody is a novel immune-oncology antibody with potent anti-tumor activity generated using HBM\'s proprietary H2L2 Harbour Mice platform.\nBy leveraging its innovative discovery engine based on the Harbour Mice antibody platforms, HBM has built a sustained capability to deliver novel antibody therapeutics in the field of oncology and immunology.
  • Following the previously reported monoclonal antibody against a novel target CCR8, HBM now reports another first-in-class therapeutic antibody targeting a novel immune checkpoint - B7H7.

Gennao Bio Presents New Data on Novel Gene Monoclonal Antibody Platform Technology at the American Association for Cancer Research (AACR) 2021 Annual Meeting

Saturday, April 10, 2021 - 1:30pm

The data were presented at the American Association for Cancer Research (AACR) Annual Meeting 2021.

Key Points: 
  • The data were presented at the American Association for Cancer Research (AACR) Annual Meeting 2021.
  • The full abstract and poster presentation can be accessed on the AACR annual meeting website, www.aacr.org , through June 21, 2021.
  • Gennao Bio is a privately-held genetic medicines company developing first-in-class targeted nucleic acid therapeutics utilizing its proprietary gene monoclonal antibody (GMAB) platform technology.
  • Gennao Bio is developing this delivery system with an initial focus on oncology and monogenic skeletal muscle diseases.

Zymeworks Showcases Preclinical Assets, Including New Therapeutic Platform, ProTECT™, and Zanidatamab Mechanisms of Action at AACR Annual Meeting

Saturday, April 10, 2021 - 1:30pm

We continue to exploit these approaches along with our bispecific, antibody-drug conjugate, and immunomodulatory platforms to build a diverse therapeutic pipeline.

Key Points: 
  • We continue to exploit these approaches along with our bispecific, antibody-drug conjugate, and immunomodulatory platforms to build a diverse therapeutic pipeline.
  • Zanidatamab is a bispecific antibody, based on Zymeworks Azymetric platform, that can simultaneously bind two non-overlapping epitopes of HER2, known as biparatopic binding.
  • Zymeworks suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of highly differentiated product candidates.
  • Zymeworks is also advancing a deep preclinical pipeline in oncology (including immuno-oncology agents) and other therapeutic areas.

Xencor Presents Data from Multiple Preclinical XmAb® Bispecific Antibody and Cytokine Programs at the AACR Annual Meeting 2021

Saturday, April 10, 2021 - 1:30pm

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced the presentation of new data from multiple preclinical XmAb bispecific antibody programs and its preclinical IL-12-Fc cytokine program at the American Association for Cancer Research (AACR) Annual Meeting, being held virtually April 10-15, 2021.

Key Points: 
  • Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced the presentation of new data from multiple preclinical XmAb bispecific antibody programs and its preclinical IL-12-Fc cytokine program at the American Association for Cancer Research (AACR) Annual Meeting, being held virtually April 10-15, 2021.
  • "In 2021, we anticipate submitting an IND for XmAb819, our lead XmAb 2+1 CD3 bispecific antibody targeting ENPP3, and initiating a Phase 1 study in early 2022.
  • Xencor engineered PD-L1 x CD28 bispecific antibodies to provide conditional co-stimulation of T cells, activating them when bound to tumor cells.
  • A PD-L1 x CD28 bispecific antibody, therefore, may promote CD28 co-stimulation and simultaneously block CD28's suppression by PD-L1.